

1
2 **A Short-Term Low Magnesium Diet Reduces Autoimmune**
3 **Arthritis Severity and Synovial Tissue Gene Expression.**

4
5
6
7
8
9
10
11 Max Brenner¹, Teresina Laragione², Pércio S. Gulko^{2,3}

12
13
14
15
16
17 ¹ The Feinstein Institute for Medical Research.

18 ² Division of Rheumatology, Department of Medicine, Icahn School of Medicine at Mount Sinai
19 New York, NY 10029.

20
21
22
23 ³ Address correspondence and reprint requests to:

24 Pércio S. Gulko M.D.

25 Division of Rheumatology

26 Department of Medicine

27 Icahn School of Medicine at Mount Sinai

28 One Gustave L. Levy Place, box 1244

29 New York, NY 10029.

30 Phone: (212) 241-0670

31 E-mail address: percio.gulko@mssm.edu

32
33
34
35 **Running title:** *Magnesium regulates arthritis severity and synovial gene expression.*

36 **Acknowledgements:** *This research did not receive any specific grant from funding agencies*
37 *in the public, commercial, or not-for-profit sectors.*

39 **ABSTRACT**

40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69

Magnesium has been suggested to have anti-inflammatory properties in short-term mostly in vitro studies. To examined the effect of dietary magnesium modifications in arthritis severity and joint damage DA rats were placed on one of three diet regimens before the induction of autoimmune pristane-induced arthritis (PIA): a four-week low-magnesium diet, normal diet and a magnesium-supplemented diet. The diets were switched to a normal diet fourteen days after the induction of PIA (typical time of disease onset). Arthritis severity was scored for 38 days, and joints examined by histology and qPCR for pro-inflammatory genes. Rats on the low-magnesium diet were significantly and reproducibly protected and had 70% lower median arthritis severity score, with preservation of normal joint histology without erosive changes. Rats on the normal or magnesium-supplemented diets were not protected and developed equally severe and erosive disease. While the dietary modifications were at disease onset (day fourteen post-induction), the protective effect of the short-term low-magnesium diet persisted, suggesting a lasting effect on a critical pathogenic pathway. Rats on the low-magnesium diet had significant reduction in synovial tissue expression of IL-6, RORA and RORC, which are genes required for the development of Th17 T cells. This study revealed a novel role for dietary magnesium in the regulation of autoimmune arthritis and opens new possibilities for the treatment of autoimmune diseases such as RA and psoriatic arthritis with short courses of dietary or drug-induced modulations of magnesium levels.

Keywords: *joint damage, erosions, diet, rheumatoid, models.*

70 **INTRODUCTION**

71

72 Magnesium is the second most abundant intracellular ion and plays an important role in
73 enzymatic function and trans-membrane ion transport. Magnesium administration has been
74 used to treat pre-eclampsia for decades and its use in short-term mostly *in vitro* experiments
75 was recently shown to reduce levels of TNF α , IL-1 β , IL-6 and other inflammatory mediators, as
76 well as to prevent NF κ B activation in experiments with endothelial cells, macrophages and
77 placental explants, suggesting a suppressive effect predominantly on innate immune
78 responses (1, 4, 8, 12, 13). TNF α , IL-1 β , IL-6 and NF κ B are central to rheumatoid arthritis (RA)
79 pathogenesis and joint damage. Therefore, we hypothesized that magnesium supplementation
80 would suppress these inflammatory mediators and reduce disease severity and joint damage
81 in arthritis, while magnesium depletion would have the opposite effect.

82

83 In the present study we report the new discovery that a short-term low magnesium diet, and
84 not magnesium supplementation, significantly reduced arthritis severity, joint inflammation and
85 joint damage. This was associated with reduced synovial tissue expression of pro-
86 inflammatory cytokines and transcription factors implicated in the development of Th17. These
87 observations suggest that manipulation of magnesium levels could be a potentially novel
88 strategy to treat RA, as well as other autoimmune and inflammatory diseases.

89

90 **MATERIAL AND METHODS**

91

92 **Rats.** Male DA/Hsd rats were purchased from Harlan (Indianapolis, IN) and housed under
93 specific pathogen-free conditions. All experiments involving rats were conducted under a
94 protocol approved by the Feinstein Institute's Institutional Animal Care and Use Committee
95 (the Gulko lab has since moved to Mount Sinai).

96

97 **Dietary magnesium modifications.** Rats were assigned to one of three dietary treatments
98 groups prior to the induction of pristane-induced arthritis (PIA): **a) low-magnesium diet:** a diet
99 containing 50ppm of magnesium, or 0.06 g/Kg (Harlan, IN) started two weeks before and
100 continued for an additional two weeks following the administration of pristane, at which point
101 the diet was switched to a regular diet for the rest of the 38 days of the arthritis experiments; **b)**
102 **a regular diet:** a diet containing normal amounts of magnesium 500ppm or 0.8 g/Kg (Harlan,
103 IN) administered before the induction of arthritis and throughout the 38 days of arthritis;
104 **c) magnesium-supplemented regular diet:** the same regular diet described above with
105 magnesium 500ppm or 0.8 g/Kg (Harlan, IN), with magnesium chloride 0.5% supplementation
106 in the drinking water *ad lib* for one week before and two weeks after the administration of
107 pristane to induce arthritis, followed by simple continuation of the regular diet for the remaining
108 of the 38 days of the arthritis experiment. By the typical day of arthritis onset (day 14 post
109 administration of pristane) all rats were on the regular chow diet.

110

111 **Diet/chow specific details:** The diets were purchased from Teklad/Harlan Laboratories
112 (Madison, WI). Rats received identical diets, except for the amount of magnesium (low
113 magnesium chow, normal magnesium chow, and normal magnesium chow plus magnesium
114 choride 0.5% supplementation in the drinking water). Specifically the diets had the following
115 contents (g/Kg) and were irradiated: protein (17.7), carbohydrates (64.4), fat (6.2), Casein
116 (200), DL-Methionine (3.0), Sucrose (415), Corn Starch (250), Soybean Oil (60), Cellulose
117 (30), Vitamin Mix (Teklad 40060) (10), Ethoxyquin (antioxidant) (0.01), Calcium Phosphate,

118 dibasic (13.7), Potassium Citrate (monohydrate) (7.7), Calcium Carbonate (4.8), Sodium
119 Chloride (2.6), Potassium Sulfate (1.82), Ferric Citrate (0.25), Manganous Carbonate (0.12),
120 Zinc Carbonate (0.056), Chromium Potassium Sulfate (dodecahydrate) (0.02), Cupric
121 Carbonate (0.012), Potassium Iodate (0.0004), and Sodium Selenite, (pentahydrate) (0.0004).
122 The only difference is in the amount of magnesium as the low magnesium diet has magnesium
123 oxide 0.06g/Kg of chow (Mg 50ppm), the normal (regular) magnesium diet has magnesium
124 oxide 0.822g/Kg of chow (Mg 500ppm).

125
126 **Induction of PIA.** Eight to twelve-week old rats received 150 µl of pristane (2,6,10,14-
127 tetramethylpentadecane, SIGMA-Aldrich Chemical Co., Milwaukee, WI) by intradermal
128 injection (day zero) (15) (2). The dose was divided in two injection sites at the base of the tail.

129
130 **Arthritis scoring.** We used a previously described arthritis scoring system (2) that evaluates
131 individual joints and measures arthritis severity according to joint size as follows: a)
132 interphalangeal, metacarpophalangeal and metatarsophalangeal joints in each one of the four
133 lateral digits were scored 0=no arthritis; 1=arthritis present; b) wrist, mid-forepaw, ankle and
134 midfoot joints were scored 0=normal; 1=minimal swelling; 2=moderate swelling; 3=severe
135 swelling; 4=severe swelling and non-weight bearing. The scores from all involved joints were
136 added (maximum score per rat=80). The same observer obtained all arthritis scores. The
137 arthritis severity index (ASI), which is a measure of disease severity over time, was determined
138 for each animal by adding the individual arthritis scores obtained over the course of the
139 experiment. The ASI correlates with histological changes and damage (2).

140
141 **Histology and histological scoring.** At the end of the arthritis observation period the right
142 hind paw was fixed in 10% formaldehyde, and then decalcified with a solution containing
143 hydrochloric acid and 0.1M EDTA (Cal-Ex, Fisher Scientific, Fairlawn, NJ). Tissues were
144 sectioned, embedded in paraffin, and slides prepared and stained with hematoxylin-eosin and
145 safranin-O. Two slides were prepared per rat and the one with the best quality (section and
146 staining) used for histology scoring without knowledge of treatment. A previously described
147 comprehensive histological scoring system was used (2). Briefly, tibio-talar, talus-calcaneal
148 and midfoot joints were histologically scored for the following parameters:

- 149 1) *Synovial inflammation.* Five high-power magnification fields (HMF) were scored for the
150 percentage of infiltrating mononuclear cells as follows: 0=absent; 1=mild (1-10%);
151 2=moderate (11-50%); 3=severe (51-100%). The mean of the five HMF was used for
152 analyses.
- 153 2) *Synovial hyperplasia.* 0=absent; 1=mild (5-10 layers); 2=moderate (11-20 layers);
154 3=severe (>20 layers).
- 155 3) *Extension of pannus formation.* Based on the reader's impression: 0=absent; 1=mild;
156 2=moderate; 3=severe.
- 157 4) *Synovial fibrosis.* 0=absent; 1=mild (1-10%); 2=moderate (11-50%); 3=severe (51-
158 100%).
- 159 5) *Synovial vascularity (angiogenesis).* The number of vessels was counted in five HMF of
160 synovial tissue, and the mean used for analyses.
- 161 6) *Cartilage erosion.* Percentage of the cartilage surface that was eroded: 0=absent;
162 1=mild (1-10%); 2=moderate (11-50%); 3=severe (51-100%).
163 *one erosion.* 0=none; 1=minor erosion(s) observed only at HMF; 2=moderate
164 erosion(s) observed at low magnification; 3=severe transcortical erosion(s).

165

166 **Quantitative PCR (qPCR).** Synovial tissues were collected from the rat ankles after the
167 completion of the arthritis observation period and immediately frozen in liquid nitrogen. Tissues
168 were subsequently homogenized and total RNA isolated with the RNeasy Kit (Qiagen) and
169 digested with DNase (Qiagen). 200ng of total RNA from each sample were used for cDNA
170 synthesis (ABI high capacity reverse transcription kit, Life Technologies). qPCR reactions were
171 set using Thermo Scientific Absolute Blue qPCR mix (Waltham, MA), 200nM of forward and
172 reverse primers, 100nM of gene-specific probes TaqMan (ABI) 5' exonuclease or Roche
173 Universal Probe Library (Roche), and 150-200ng of cDNA. Reactions were run on a
174 LightCycler 480 thermocycler (Roche) using Relative Quantitative Software (Roche). Primers
175 and probes used for rat interleukin-1 beta (IL-1 β), IL-6, IL-17A, C-X-C motif chemokine ligand
176 10 (CXCL10), RORA (RAR-related orphan receptor alpha), RORC (RAR-related orphan
177 receptor C), and GAPDH genes have been previously reported (2, 5). GAPDH was used as
178 endogenous control. *Ct* (threshold cycle) values were obtained and analyzed with the
179 Sequence Detection System software version 1.9.1 (ABI). *Ct* (threshold cycle) values were
180 adjusted for GAPDH in each sample (ΔCt). ΔCt values were compared using the t-test, and
181 fold differences in gene expression between different concentrations of magnesium were
182 determined using the $2^{-\Delta\Delta Ct}$ method (10).
183

184 **Statistical analyses.** Non-normally distributed data were compared with the Mann-Whitney
185 test for two group comparisons. The t-test was used to compare means, and a paired t-test to
186 compare serum levels of magnesium. One-way ANOVA with the Tukey's multiple comparison
187 test was used to compare histology scores. A p-value of 0.05 or less was regarded as
188 significant. All statistical analyses were done with SigmaStat 3.0 and GraphPad Prism.
189

190 RESULTS

191
192 **A short-term low-magnesium diet reduces arthritis severity.** Serum levels of magnesium
193 were measured at the beginning of the diet and again on the last day of the diet (days -14 and
194 14 related to the pristane administration). Serum levels of magnesium remained stable in the
195 normal magnesium diet, but were significantly decreased in the low magnesium diet (figure 1).
196

197 The low-magnesium diet group developed a significantly milder form of arthritis, with minimal
198 disease (figure 2A) and a nearly 70% lower median ASI, compared with the regular diet and
199 with the magnesium-supplemented group (low-magnesium group median ASI=93.5; normal-
200 magnesium group median ASI=271.5; magnesium-supplemented group median ASI=251.75;
201 low-magnesium versus each of the other groups $P=0.004$; Mann-Whitney test; figure 2A-C).
202 These observations were confirmed in a second independent experiment with 12-13 rats per
203 group (data not shown). The clinical benefit could be detected as early as day 18 and persisted
204 throughout the 38-day scoring period despite switching the diet back to the regular normal
205 magnesium diet on day 14.
206

207 The magnesium-supplemented group developed PIA as severe as the group receiving regular
208 diet and had no evidence of protection (figure 2A).
209

210 **Low-magnesium diet reduced synovial inflammation and joint damage.** Histology
211 analyses further confirmed the clinical data and revealed that the low-magnesium diet group
212 had nearly no synovial abnormalities and preserved a normal joint architecture (figure 2E),
213 while the regular diet and magnesium-supplemented groups had pronounced inflammatory cell

214 infiltration ($P<0.05$), synovial hyperplasia ($P<0.05$), and bone and cartilage erosions ($P=0.04$;
215 figure 2D; Table 1). Three individual histology parameters (inflammatory infiltration, synovial
216 hyperplasia and pannus extension) remained statistically significant after adjustments of P
217 values for multiple comparisons (Bonferroni correction for seven variables). These
218 observations demonstrated that short-term low magnesium intake and reduced serum levels of
219 magnesium during the induction of PIA had a long-lasting and protective effect on arthritis
220 severity and joint damage.

221

222 **Low-magnesium diet rats had reduced synovial expression of key pro-inflammatory**
223 **genes, including those required for Th17 development.** qPCR analyses of inflammatory
224 mediators in synovial tissues from low-magnesium diet rats with PIA revealed significantly
225 reduced levels of IL-6, RORA and RORC, all which are required for T cell helper 17 (Th17)
226 development (figure 3A and B). IL-17A was not expressed in the synovial tissues of rats in the
227 low magnesium diet, but was still expressed (day 39) in three out of eight rats from the regular
228 diet group. Additional genes involved in synovial inflammation and joint damage such as IL-1 β
229 and CXCL10 were also reduced in synovial tissues from the low-magnesium diet group.

230

231 **DISCUSSION**

232

233 Magnesium has been used for decades to prevent seizures in pre-eclampsia (14). Recently,
234 pro-inflammatory mediators such as TNF α and IL-6 were implicated in the pathogenesis of pre-
235 eclampsia (14) and studies conducted over short periods of time (hours) with macrophage,
236 endothelial cells or placental explants showed that magnesium supplementation was able to
237 reduce levels of these cytokines and suppress NF κ B activation (4, 8, 12, 13). Given the central
238 role that TNF α and IL-6 have in RA and joint damage, we hypothesized that magnesium
239 supplementation would reduce levels of these cytokines, reducing disease severity and joint
240 damage in PIA. However, we observed the opposite effect where magnesium supplementation
241 had no effect in disease severity, while a short-term low-magnesium diet had a major,
242 significant, lasting and protective effect rendering DA rats nearly resistant to PIA.

243

244 This new discovery raised the possibility that the low magnesium diet was targeting a cell type
245 not examined in previous studies that mostly focused on short-term effects over hours on
246 components of the innate immune response. We considered that magnesium could be
247 affecting T cells, which were not examined in other studies and are required for the
248 development of PIA (15).

249

250 Magnesium, including two magnesium channels TRPM7 and MAGT1, has been implicated in
251 the regulation of thymic T cell development (6, 9). MAGT1 has also been shown to regulate
252 TCR signaling (9). Therefore, we considered that the short-term low serum level of magnesium
253 might affect the differentiation of T cell subsets such as pathogenic Th17. IL-17-producing
254 Th17 T cells have been implicated in the pathogenesis of several autoimmune diseases
255 including RA (3, 7), colitis, and psoriasis (11). Indeed, levels of IL-17A were undetectable in
256 synovial tissues from rats fed the low magnesium diet, and the levels of Th17-driving
257 transcription factors RORA and RORC were also significantly reduced. IL-6, which among
258 several activities is involved in Th17 differentiation, also had significantly reduced expression
259 in the low magnesium diet group. IL-1 β and CXCL10 mRNA levels were also decreased in the
260 low magnesium diet group. Therefore, the low magnesium diet could conceivably affect Th17
261 differentiation or migration into the synovial tissues.

262

263 IL-1 β , IL-6 and CXCL10 are key pro-inflammatory mediators produced by fibroblast-like
264 synoviocytes (FLS) and synovial macrophages, and implicated in arthritis pathogenesis, FLS
265 invasiveness and joint damage. These observations suggested that the effect of reduced
266 magnesium concentrations could include not only Th17, but also synoviocyte-mediated joint
267 damage.

268

269 In conclusion, we describe a novel role for magnesium in the regulation of arthritis severity and
270 joint damage. This new discovery and the effect of the low magnesium diet on Th17-related
271 and other pro-inflammatory genes raise the possibility of using a short-term diet or short-term
272 use of magnesium lowering agents, or targeting magnesium channels or transporters as
273 adjuvants in the treatment of inflammatory arthritis and autoimmune diseases such as RA.

274 **Table 1. Histology scoring analyses.** Paws from the experiment described on figure 2A
275 scored using a previously described quantitative scoring system. The low magnesium diet
276 group had significantly lower inflammatory cell infiltration (inflammation) ($P<0.05$), lower
277 synovial hyperplasia (synov hyperpl) ($P<0.05$) and lower bone erosions scores ($P=0.04$)
278 compared with the magnesium supplemented group and with the normal diet group.

279

280 **FIGURE LEGENDS**

281 **Figure 1. Serum Levels of magnesium at the beginning and end of the diet.** Magnesium
282 levels before starting the low magnesium or regular diet (day -14) and at the last day of the diet
283 (day 14) relative to the day of induction of pristane induced arthritis (PIA, day zero) revealed a
284 significant reduction in the low magnesium diet group (* $P<0.001$; paired t-test). At day 14
285 serum magnesium levels in the low magnesium diet group were also significantly lower than
286 the regular diet group (# $P<0.0001$; t-test).

287 **Figure 2. A magnesium-deficient diet had a significant and lasting protective effect on**
288 **arthritis severity and joint damage. (A)** Arthritis severity score curves over time with a
289 cumulative arthritis severity score reduction of nearly 70% in the low magnesium diet group
290 (Mg-) compared with normal magnesium chow (normal; $P=0.004$, Mann-Whitney test) and
291 magnesium supplemented diet (normal chow plus magnesium chloride 0.5% in the water;
292 Mg+) ($P\leq 0.001$) (shown as mean \pm S.E.M). **(B)** Normal diet rat with PIA had severe arthritis and
293 ankle/paw swelling while **(C)** the low magnesium diet rats had nearly no inflammation or
294 arthritis. Histology of **(D)** normal diet rats with PIA revealed pronounced synovial hyperplasia,
295 synovial inflammation and erosive changes (black arrow), while **(E)** the low magnesium rats
296 developed nearly no disease with preservation of a normal joint histology. Histology (H&E;
297 100X magnification).

298 **Figure 3. The low Magnesium diet group had reduced synovial expression of cytokines**
299 **and genes implicated in the development of Th17 T cells, or on their homing into**
300 **inflammatory sites. A.** Cycle detection threshold (Ct) levels and standard deviation (S.D.) of
301 qPCRs analyses of synovial tissues (* $P<0.01$, t-test). **B.** Fold-difference between low
302 magnesium diet group and the regular diet group.

303

304


305

306 REFERENCES

307

- 308 1. **Amash A, Holcberg G, Sheiner E, and Huleihel M.** Magnesium sulfate normalizes
309 placental interleukin-6 secretion in preeclampsia. *J Interferon Cytokine Res* 30: 683-
310 690, 2010.
- 311 2. **Brenner M, Meng H, Yarlett N, Griffiths M, Remmers E, Wilder R, and Gulko P.** The
312 non-MHC quantitative trait locus Cia10 contains a major arthritis gene and regulates
313 disease severity, pannus formation and joint damage. *Arthritis Rheum* 52: 322-332.,
314 2005.
- 315 3. **Chabaud M, Lubberts E, Joosten L, van Den Berg W, and Miossec P.** IL-17 derived
316 from juxta-articular bone and synovium contributes to joint degradation in rheumatoid
317 arthritis. *Arthritis Res* 3: 168-177., 2001.
- 318 4. **Dowling O, Chatterjee PK, Gupta M, Tam Tam HB, Xue X, Lewis D, Rochelson B,
319 and Metz CN.** Magnesium sulfate reduces bacterial LPS-induced inflammation at the
320 maternal-fetal interface. *Placenta* 33: 392-398, 2012.
- 321 5. **Jenkins E, Brenner M, Laragione T, and Gulko PS.** Synovial expression of Th17-
322 related and cancer-associated genes is regulated by the arthritis severity locus Cia10.
323 *Genes Immun* 13: 221-231, 2012.
- 324 6. **Jin J, Desai BN, Navarro B, Donovan A, Andrews NC, and Clapham DE.** Deletion of
325 *Trpm7* disrupts embryonic development and thymopoiesis without altering Mg²⁺
326 homeostasis. *Science* 322: 756-760, 2008.
- 327 7. **Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S,
328 Inoue K, Kamatani N, Gillespie MT, Martin TJ, and Suda T.** IL-17 in synovial fluids
329 from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. *J*
330 *Clin Invest* 103: 1345-1352, 1999.
- 331 8. **Lee CY, Jan WC, Tsai PS, and Huang CJ.** Magnesium sulfate mitigates acute lung
332 injury in endotoxemia rats. *J Trauma* 70: 1177-1185; discussion 1185, 2011.
- 333 9. **Li FY, Chaigne-Delalande B, Kanellopoulou C, Davis JC, Matthews HF, Douek DC,
334 Cohen JI, Uzel G, Su HC, and Lenardo MJ.** Second messenger role for Mg²⁺
335 revealed by human T-cell immunodeficiency. *Nature* 475: 471-476, 2011.
- 336 10. **Livak KJ, and Schmittgen TD.** Analysis of relative gene expression data using real-
337 time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25: 402-408,
338 2001.
- 339 11. **Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle
340 S, Thurston HJ, Papavassilis C, and Richards HB.** Efficacy and safety of
341 secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized,
342 double-blind, placebo-controlled phase II dose-ranging study. *Br J Dermatol* 168: 412-
343 421, 2013.
- 344 12. **Rochelson B, Dowling O, Schwartz N, and Metz CN.** Magnesium sulfate suppresses
345 inflammatory responses by human umbilical vein endothelial cells (HuVECs) through
346 the NfKappaB pathway. *J Reprod Immunol* 73: 101-107, 2007.
- 347 13. **Sugimoto J, Romani AM, Valentin-Torres AM, Luciano AA, Ramirez Kitchen CM,
348 Funderburg N, Mesiano S, and Bernstein HB.** Magnesium decreases inflammatory
349 cytokine production: a novel innate immunomodulatory mechanism. *J Immunol* 188:
350 6338-6346, 2012.

- 351 14. **Uzan J, Carbonnel M, Piconne O, Asmar R, and Ayoubi JM.** Pre-eclampsia:
352 pathophysiology, diagnosis, and management. *Vasc Health Risk Manag* 7: 467-474,
353 2011.
- 354 15. **Vingsbo C, Sahlstrand P, Brun JG, Jonsson R, Saxne T, and Holmdahl R.** Pristane-
355 induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease
356 course influenced by both major histocompatibility complex and non-major
357 histocompatibility complex genes. *Am J Pathol* 149: 1675-1683, 1996.
- 358








Table 1. Histology scoring and analyses of the ankles of rats with PIA*.

Scoring Parameter	Mg Suppl (n=5)		Regular (n=5)		Low Mg (n=5)		P-value ^a
	mean	S.D	mean	S.D	mean	S.D	
Inflammatory Infiltration (0-3)	1.73 ± 0.51		2.24 ± 0.65		0.40 ± 0.00		≤0.05; Low Mg vs Reg and Mg Supp
Synovial hyperplasia (0-3)	2.00 ± 1.41		2.60 ± 0.55		0.00 ± 0.00		≤0.05; Low Mg vs Reg and Mg Supp
Pannus extension (0-3)	2.00 ± 0.71		2.20 ± 0.45		0.60 ± 0.89		≤0.05; Low Mg vs Reg and Mg Supp
Fibrosis (0-3)	0.20 ± 0.45		0.20 ± 0.45		0.20 ± 0.45		>0.05
Vessels/HMF; counts.	4.92 ± 2.16		3.36 ± 2.09		3.40 ± 1.46		>0.05
Bone erosions (0-3)	2.40 ± 1.34		2.40 ± 1.34		0.40 ± 0.89		≤0.05; Low Mg vs Reg and Mg Supp
Cartilage erosions (0-3)	0.20 ± 0.45		1.40 ± 1.35		0.00 ± 0.00		≤0.05; Low Mg vs Reg

* Mg Suppl=Mg Supplemented diet; Regular=regular diet; Low Mg = Low magnesium diet. HMF=high-magnification field.

^a One-way ANOVA with Tukey's multiple comparisons test; Grey cell indicate significant $P \leq 0.05$; S.D.=standard deviation.

